
C4 Therapeutics, Inc. (NASDAQ:CCCC – Free Report) – Brookline Capital Markets raised their FY2026 earnings per share estimates for C4 Therapeutics in a report issued on Thursday, November 5th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($0.69) per share for the year, up from their previous forecast of ($0.80). The consensus estimate for C4 Therapeutics’ current full-year earnings is ($0.73) per share. Brookline Capital Markets also issued estimates for C4 Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2027 earnings at ($0.89) EPS and FY2028 earnings at ($1.57) EPS.
A number of other research firms have also weighed in on CCCC. Evercore lowered C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 2nd. Guggenheim started coverage on shares of C4 Therapeutics in a report on Friday, November 6th. They issued a “buy” rating and a $6.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on shares of C4 Therapeutics in a research report on Friday, October 9th. They issued an “overweight” rating and a $10.00 price objective for the company. Wall Street Zen cut shares of C4 Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.
C4 Therapeutics Stock Performance
Shares of CCCC opened at $2.89 on Tuesday. C4 Therapeutics has a 52-week low of $1.69 and a 52-week high of $5.17. The stock’s 50-day simple moving average is $3.17 and its 200 day simple moving average is $3.24. The stock has a market capitalization of $379.51 million, a price-to-earnings ratio of -4.01 and a beta of 3.16.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.03. C4 Therapeutics had a negative return on equity of 37.71% and a negative net margin of 282.22%. The company had revenue of $8.47 million during the quarter, compared to analysts’ expectations of $8.52 million.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. grew its stake in C4 Therapeutics by 170.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 21,924 shares of the company’s stock worth $73,000 after buying an additional 13,819 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in shares of C4 Therapeutics during the 3rd quarter worth $34,000. Allspring Global Investments Holdings LLC purchased a new position in C4 Therapeutics in the third quarter worth $239,000. Candriam S.C.A. grew its position in C4 Therapeutics by 53.6% in the third quarter. Candriam S.C.A. now owns 2,760,346 shares of the company’s stock worth $9,226,000 after acquiring an additional 963,409 shares in the last quarter. Finally, Alps Advisors Inc. grew its position in C4 Therapeutics by 44.2% in the third quarter. Alps Advisors Inc. now owns 161,828 shares of the company’s stock worth $539,000 after acquiring an additional 49,614 shares in the last quarter. Hedge funds and other institutional investors own 78.81% of the company’s stock.
C4 Therapeutics Company Profile
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it develops medicines designed to selectively remove disease-causing proteins, with a focus on cancer. The company uses its TORPEDO platform to design targeted protein degraders. These molecules are intended to bind a target protein and recruit the cell’s natural protein-disposal machinery, leading to the protein’s breakdown. C4 Therapeutics’ research and development programs include oral small-molecule candidates for oncology.
Featured Stories
- Five stocks we like better than C4 Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
